tirzepatide (Mounjaro)

following a full submission:

tirzepatide (Mounjaro®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.

SMC restriction: in addition to other oral anti-diabetic medicines as an option when glucagon-like peptide-1 (GLP-1) receptor agonists would be considered.

In three phase III studies, tirzepatide demonstrated statistically significant reductions from baseline in HbA1c compared with a GLP-1 receptor agonist and two basal insulins.

SMC cannot recommend the use of tirzepatide as monotherapy when metformin is considered inappropriate due to intolerance or contraindications as the company’s submission related only to its use in addition to other medicinal products for the treatment of diabetes.